{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T03:16:29Z","timestamp":1784258189232,"version":"3.55.0"},"reference-count":51,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T00:00:00Z","timestamp":1568592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["T1062-B33"],"award-info":[{"award-number":["T1062-B33"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["I-2872-B28"],"award-info":[{"award-number":["I-2872-B28"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ingrid Shaker Nessman Cancer Research Association","award":["MAH"],"award-info":[{"award-number":["MAH"]}]},{"DOI":"10.13039\/501100004061","name":"Oesterreichische Nationalbank","doi-asserted-by":"publisher","award":["16912"],"award-info":[{"award-number":["16912"]}],"id":[{"id":"10.13039\/501100004061","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Malignant pleural mesothelioma (MPM) is a devastating malignancy with limited therapeutic options. Fibroblast growth factor receptors (FGFR) and their ligands were shown to contribute to MPM aggressiveness and it was suggested that subgroups of MPM patients could benefit from FGFR-targeted inhibitors. In the current investigation, we determined the expression of all four FGFRs (FGFR1\u2013FGFR4) by immunohistochemistry in tissue samples from 94 MPM patients. From 13 of these patients, we were able to establish stable cell lines, which were subjected to FGFR1\u20134 staining, transcript analysis by quantitative RT-PCR, and treatment with the FGFR inhibitor infigratinib. While FGFR1 and FGFR2 were widely expressed in MPM tissue and cell lines, FGFR3 and FGFR4 showed more restricted expression. FGFR1 and FGFR2 showed no correlation with clinicopathologic data or patient survival, but presence of FGFR3 in 42% and of FGFR4 in 7% of patients correlated with shorter overall survival. Immunostaining in cell lines was more homogenous than in the corresponding tissue samples. Neither transcript nor protein expression of FGFR1\u20134 correlated with response to infigratinib treatment in MPM cell lines. We conclude that FGFR3 and FGFR4, but not FGFR1 or FGFR2, have prognostic significance in MPM and that FGFR expression is not sufficient to predict FGFR inhibitor response in MPM cell lines.<\/jats:p>","DOI":"10.3390\/cells8091091","type":"journal-article","created":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T03:31:46Z","timestamp":1568691106000},"page":"1091","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Expression of FGFR1\u20134 in Malignant Pleural Mesothelioma Tissue and Corresponding Cell Lines and its Relationship to Patient Survival and FGFR Inhibitor Sensitivity"],"prefix":"10.3390","volume":"8","author":[{"given":"Gregor","family":"Vlacic","sequence":"first","affiliation":[{"name":"University Clinic for Respiratory and Allergic Diseases Golnik, 4204 Golnik, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mir A.","family":"Hoda","sequence":"additional","affiliation":[{"name":"Translational Thoracic Oncology Laboratory, Division of Thoracic Surgery, Department of Surgery, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Klikovits","sequence":"additional","affiliation":[{"name":"Translational Thoracic Oncology Laboratory, Division of Thoracic Surgery, Department of Surgery, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Sinn","sequence":"additional","affiliation":[{"name":"Translational Thoracic Oncology Laboratory, Division of Thoracic Surgery, Department of Surgery, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Gschwandtner","sequence":"additional","affiliation":[{"name":"Translational Thoracic Oncology Laboratory, Division of Thoracic Surgery, Department of Surgery, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Mohorcic","sequence":"additional","affiliation":[{"name":"University Clinic for Respiratory and Allergic Diseases Golnik, 4204 Golnik, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Schelch","sequence":"additional","affiliation":[{"name":"Institute of Cancer Research, Department of Medicine I, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Pirker","sequence":"additional","affiliation":[{"name":"Institute of Cancer Research, Department of Medicine I, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Peter-V\u00f6r\u00f6smarty","sequence":"additional","affiliation":[{"name":"Institute of Cancer Research, Department of Medicine I, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"Brankovic","sequence":"additional","affiliation":[{"name":"Institute of Cancer Research, Department of Medicine I, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balazs","family":"Dome","sequence":"additional","affiliation":[{"name":"Translational Thoracic Oncology Laboratory, Division of Thoracic Surgery, Department of Surgery, Medical University of Vienna, 1090 Vienna, Austria"},{"name":"Department of Tumor Biology, National Koranyi Institute of Pulmonology, 1085 Budapest, Hungary"},{"name":"Department of Thoracic Surgery, National Institute of Oncology-Semmelweis University, 1085 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktoria","family":"Laszlo","sequence":"additional","affiliation":[{"name":"Translational Thoracic Oncology Laboratory, Division of Thoracic Surgery, Department of Surgery, Medical University of Vienna, 1090 Vienna, Austria"},{"name":"Department of Tumor Biology, National Koranyi Institute of Pulmonology, 1085 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Cufer","sequence":"additional","affiliation":[{"name":"University Clinic for Respiratory and Allergic Diseases Golnik, 4204 Golnik, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ales","family":"Rozman","sequence":"additional","affiliation":[{"name":"University Clinic for Respiratory and Allergic Diseases Golnik, 4204 Golnik, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Klepetko","sequence":"additional","affiliation":[{"name":"Translational Thoracic Oncology Laboratory, Division of Thoracic Surgery, Department of Surgery, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina","family":"Grasl-Kraupp","sequence":"additional","affiliation":[{"name":"Institute of Cancer Research, Department of Medicine I, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4341-4153","authenticated-orcid":false,"given":"Balazs","family":"Hegedus","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, University Medicine Essen-Ruhrlandklinik, 45239 Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0014-1658","authenticated-orcid":false,"given":"Walter","family":"Berger","sequence":"additional","affiliation":[{"name":"Institute of Cancer Research, Department of Medicine I, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izidor","family":"Kern","sequence":"additional","affiliation":[{"name":"University Clinic for Respiratory and Allergic Diseases Golnik, 4204 Golnik, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5486-9340","authenticated-orcid":false,"given":"Michael","family":"Grusch","sequence":"additional","affiliation":[{"name":"Institute of Cancer Research, Department of Medicine I, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,9,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nrc.2017.42","article-title":"Novel insights into mesothelioma biology and implications for therapy","volume":"17","author":"Yap","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1146\/annurev-publhealth-031811-124704","article-title":"The worldwide pandemic of asbestos-related diseases","volume":"34","author":"Stayner","year":"2013","journal-title":"Annu. Rev. Public Health"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.jtho.2018.06.011","article-title":"Scientific Advances and New Frontiers in Mesothelioma Therapeutics","volume":"13","author":"Mutti","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","article-title":"Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): A multicentre, open-label, randomised, non-comparative, phase 2 trial","volume":"20","author":"Scherpereel","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat. Genet."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","article-title":"Integrative Molecular Characterization of Malignant Pleural Mesothelioma","volume":"8","author":"Hmeljak","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"5117","DOI":"10.1038\/onc.2012.5","article-title":"YAP induces malignant mesothelioma cell proliferation by upregulating transcription of cell cycle-promoting genes","volume":"31","author":"Mizuno","year":"2012","journal-title":"Oncogene"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Sekido, Y. (2018). Targeting the Hippo Pathway Is a New Potential Therapeutic Modality for Malignant Mesothelioma. Cancers, 10.","DOI":"10.3390\/cancers10040090"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"6080","DOI":"10.1038\/sj.onc.1208744","article-title":"Human and mouse mesotheliomas exhibit elevated AKT\/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth","volume":"24","author":"Altomare","year":"2005","journal-title":"Oncogene"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1158\/1541-7786.MCR-14-0038","article-title":"Nonamplified FGFR1 is a growth driver in malignant pleural mesothelioma","volume":"12","author":"Marek","year":"2014","journal-title":"Mol. Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1164\/rccm.201404-0658OC","article-title":"Fibroblast growth factor receptor inhibition is active against mesothelioma and synergizes with radio- and chemotherapy","volume":"190","author":"Schelch","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"39861","DOI":"10.18632\/oncotarget.9515","article-title":"Inhibition of FGF\/FGFR autocrine signaling in mesothelioma with the FGF ligand trap, FP-1039\/GSK3052230","volume":"7","author":"Blackwell","year":"2016","journal-title":"Oncotarget"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/1878-0261.12150","article-title":"A link between the fibroblast growth factor axis and the miR-16 family reveals potential new treatment combinations in mesothelioma","volume":"12","author":"Schelch","year":"2018","journal-title":"Mol. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1093\/carcin\/bgy018","article-title":"FGF2 and EGF induce epithelial-mesenchymal transition in malignant pleural mesothelioma cells via a MAPKinase\/MMP1 signal","volume":"39","author":"Schelch","year":"2018","journal-title":"Carcinogenesis"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1158\/1078-0432.CCR-17-1172","article-title":"Comprehensive Pharmacogenomic Profiling of Malignant Pleural Mesothelioma Identifies a Subgroup Sensitive to FGFR Inhibition","volume":"24","author":"Badhai","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1378\/chest.108.4.1122","article-title":"A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group","volume":"108","author":"Rusch","year":"1995","journal-title":"Chest"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1214479","article-title":"Mutations in DSTYK and dominant urinary tract malformations","volume":"369","author":"Sampogna","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Saucedo, L., Buffa, G.N., Rosso, M., Guillardoy, T., Gongora, A., Munuce, M.J., Vazquez-Levin, M.H., and Marin-Briggiler, C. (2015). Fibroblast Growth Factor Receptors (FGFRs) in Human Sperm: Expression, Functionality and Involvement in Motility Regulation. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0127297"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1038\/sj.bjc.6603181","article-title":"FGFR4 Arg388 allele correlates with tumour thickness and FGFR4 protein expression with survival of melanoma patients","volume":"94","author":"Streit","year":"2006","journal-title":"Br. J. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/hep.24099","article-title":"Up-regulation of the fibroblast growth factor 8 subfamily in human hepatocellular carcinoma for cell survival and neoangiogenesis","volume":"53","author":"Gauglhofer","year":"2011","journal-title":"Hepatology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/sj.bjc.6604440","article-title":"New cellular tools reveal complex epithelial-mesenchymal interactions in hepatocarcinogenesis","volume":"99","author":"Sagmeister","year":"2008","journal-title":"Br. J. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3729","DOI":"10.1158\/1078-0432.CCR-17-1507","article-title":"Nintedanib Is Active in Malignant Pleural Mesothelioma Cell Models and Inhibits Angiogenesis and Tumor Growth In Vivo","volume":"24","author":"Laszlo","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1158\/2159-8290.CD-12-0210","article-title":"FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor","volume":"2","author":"Guagnano","year":"2012","journal-title":"Cancer Discov."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1200\/JCO.2014.60.7341","article-title":"Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced Solid Tumors","volume":"33","author":"Tabernero","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3798","DOI":"10.1200\/JCO.2010.33.5208","article-title":"Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer","volume":"29","author":"Ledermann","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1158\/1078-0432.CCR-15-1127","article-title":"A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer","volume":"22","author":"Schlumberger","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S1470-2045(13)70586-2","article-title":"Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): A phase 3, double-blind, randomised controlled trial","volume":"15","author":"Reck","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/annonc\/mdt419","article-title":"Genomic aberrations in the FGFR pathway: Opportunities for targeted therapies in solid tumors","volume":"25","author":"Dienstmann","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/path.4297","article-title":"Emergence of FGFR family gene fusions as therapeutic targets in a wide spectrum of solid tumours","volume":"232","author":"Parker","year":"2014","journal-title":"J. Pathol."},{"key":"ref_30","first-page":"3395","article-title":"Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models","volume":"119","author":"Taylor","year":"2009","journal-title":"J. Clin. Investig."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.1038\/onc.2015.426","article-title":"Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression","volume":"35","author":"Kotani","year":"2016","journal-title":"Oncogene"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"5682","DOI":"10.1038\/s41388-018-0380-3","article-title":"Synergistic anti-angiogenic treatment effects by dual FGFR1 and VEGFR1 inhibition in FGFR1-amplified breast cancer","volume":"37","author":"Golfmann","year":"2018","journal-title":"Oncogene"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Jimenez-Pascual, A., and Siebzehnrubl, F.A. (2019). Fibroblast Growth Factor Receptor Functions in Glioblastoma. Cells, 8.","DOI":"10.3390\/cells8070715"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Zhang, J., Tang, P.M.K., Zhou, Y., Cheng, A.S.L., Yu, J., Kang, W., and To, K.F. (2019). Targeting the Oncogenic FGF-FGFR Axis in Gastric Carcinogenesis. Cells, 8.","DOI":"10.3390\/cells8060637"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Czyz, M. (2019). Fibroblast Growth Factor Receptor Signaling in Skin Cancers. Cells, 8.","DOI":"10.3390\/cells8060540"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Santolla, M.F., Vivacqua, A., Lappano, R., Rigiracciolo, D.C., Cirillo, F., Galli, G.R., Talia, M., Brunetti, G., Miglietta, A.M., and Belfiore, A. (2019). GPER Mediates a Feedforward FGF2\/FGFR1 Paracrine Activation Coupling CAFs to Cancer Cells toward Breast Tumor Progression. Cells, 8.","DOI":"10.3390\/cells8030223"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13287-017-0573-7","article-title":"The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells","volume":"8","author":"Pattarozzi","year":"2017","journal-title":"Stem. Cell Res. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Van Brummelen, E.M.J., Levchenko, E., Domine, M., Fennell, D.A., Kindler, H.L., Viteri, S., Gadgeel, S., Lopez, P.G., Kostorov, V., and Morgensztern, D. (2019). A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma. Investig. New Drugs.","DOI":"10.1007\/s10637-019-00783-7"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1200\/JCO.2017.72.9012","article-title":"Nintedanib Plus Pemetrexed\/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial","volume":"35","author":"Grosso","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S2213-2600(19)30139-0","article-title":"Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): A double-blind, randomised, placebo-controlled phase 3 trial","volume":"7","author":"Scagliotti","year":"2019","journal-title":"Lancet Respir. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/hep.30481","article-title":"Infigratinib Mediates Vascular Normalization, Impairs Metastasis, and Improves Chemotherapy in Hepatocellular Carcinoma","volume":"69","author":"Huynh","year":"2019","journal-title":"Hepatology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1083\/jcb.201108077","article-title":"FGFR1 cleavage and nuclear translocation regulates breast cancer cell behavior","volume":"197","author":"Chioni","year":"2012","journal-title":"J. Cell Biol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1093\/carcin\/bgu151","article-title":"Fibroblast growth factor receptor 4: A putative key driver for the aggressive phenotype of hepatocellular carcinoma","volume":"35","author":"Gauglhofer","year":"2014","journal-title":"Carcinogenesis"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1158\/2159-8290.CD-14-1029","article-title":"First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway","volume":"5","author":"Hagel","year":"2015","journal-title":"Cancer Discov."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Raja, A., Park, I., Haq, F., and Ahn, S.M. (2019). FGF19-FGFR4 Signaling in Hepatocellular Carcinoma. Cells, 8.","DOI":"10.3390\/cells8060536"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.2147\/OTT.S81659","article-title":"The prognostic significance of fibroblast growth factor receptor 4 in non-small-cell lung cancer","volume":"8","author":"Huang","year":"2015","journal-title":"Onco Targets Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.2174\/13816128113199990594","article-title":"Is fibroblast growth factor receptor 4 a suitable target of cancer therapy?","volume":"20","author":"Heinzle","year":"2014","journal-title":"Curr. Pharm. Des."},{"key":"ref_48","first-page":"1093","article-title":"Basic fibroblast growth factor in mesothelioma pleural effusions: Correlation with patient survival and angiogenesis","volume":"18","author":"Strizzi","year":"2001","journal-title":"Int. J. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Lang, L., and Teng, Y. (2019). Fibroblast Growth Factor Receptor 4 Targeting in Cancer: New Insights into Mechanisms and Therapeutic Strategies. Cells, 8.","DOI":"10.3390\/cells8010031"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Dai, S., Zhou, Z., Chen, Z., Xu, G., and Chen, Y. (2019). Fibroblast Growth Factor Receptors (FGFRs): Structures and Small Molecule Inhibitors. Cells, 8.","DOI":"10.3390\/cells8060614"},{"key":"ref_51","unstructured":"Pirker, C., Bilecz, A., Grusch, M., Mohr, T., Laszlo, V., Stockhammer, P., L\u00f6tsch, D., Gojo, J., Gabler, L., and Spiegl-Kreinecker, S. (2019). Activating TERT promoter mutations in malignant pleural mesothelioma: Association with prognosis and altered genomic signature. J. Thorac. Oncol., under review."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/8\/9\/1091\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:20:33Z","timestamp":1760188833000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/8\/9\/1091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,16]]},"references-count":51,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2019,9]]}},"alternative-id":["cells8091091"],"URL":"https:\/\/doi.org\/10.3390\/cells8091091","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,16]]}}}